The deposition of amyloid-beta (Ass) deposition is thought to begin many years prior to the onset of clinical Alzheimer's disease, but until recently it was not possible to track the longitudinal accumulation of Ass in vivo. Cross-sectional autopsy series and recent PET studies using 11CPittsburgh Compound B (PiB) suggest that a large fraction of cognitively normal older individuals harbor amyloid pathology. Our preliminary cross-sectional PiB imaging data in 100 cognitively normal (CN) older individuals have demonstrated significant variability in the level and anatomic distribution of amyloid deposition. It remains unknown whether there is a specific threshold of amyloid pathology in these CN that will predict 1) further amyloid accumulation, 2) the emergence of abnormalities on structural and functional imaging consistent with preclinical AD, and 3) subsequent cognitive decline. This project will acquire longitudinal PiB imaging, FDG-PET, resting fMRI, and detailed neuropsychological assessments in 80 CN subjects every 2 years to investigate the temporal course and anatomic pattern of amyloid accumulation (Aim 1). We will also utilize a recently developed, high-sensitivity PET camera to determine if there is a gradual accumulation of amyloid deposition that is not currently detectable with existing standard cameras (Aim 2). Finally, we will relate longitudinal amyloid accumulation to other indicators of prodromal AD, including regional FDG hypometabolism, functional MRI default network disruption, hippocampal atrophy, cortical thinning, and cognitive decline (Aim 3). This study will capitalize on an existing cohort of well-characterized clinically normal older subjects, a strong multi-disciplinary team of investigators, and state-of-the-art imaging methodology to probe the link between amyloid accumulation and the earliest brain changes associated with preclinical AD.

Public Health Relevance

The symptoms of Alzheimer's disease, a major threat to public health, are preceded by a period of brain amyloid accumulation of at least 10 years duration. The overall aim of this grant proposal is to improve our ability during the presymptomatic period to detect amyloid, to trace its accumulation at low levels, and to assess its impact on the brain, so that treatments may begin at an earlier stage of disease when damage is more limited. To accomplish this, we propose to re-enroll a group of older adults who have already participated in our amyloid research, to now undergo a set of follow-up brain scans and cognitive tests every two years. We propose to measure the buildup of amyloid over time with PiB PET and assess the impact on brain structure with MRI and function with FDG PET. We will also test a powerful new, high-sensitivity PET scanner that we predict will improve our detection of amyloid and permit us to better study it's earliest consequences.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG037497-04
Application #
8523725
Study Section
Clinical Neuroscience and Neurodegeneration Study Section (CNN)
Program Officer
Wagster, Molly V
Project Start
2010-09-01
Project End
2015-05-31
Budget Start
2013-09-01
Budget End
2014-05-31
Support Year
4
Fiscal Year
2013
Total Cost
$582,979
Indirect Cost
$253,613
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Rieckmann, Anna; Hedden, Trey; Younger, Alayna P et al. (2016) Dopamine transporter availability in clinically normal aging is associated with individual differences in white matter integrity. Hum Brain Mapp 37:621-31
Johnson, Keith A; Schultz, Aaron; Betensky, Rebecca A et al. (2016) Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 79:110-9
Hsu, David C; Mormino, Elizabeth C; Schultz, Aaron P et al. (2016) Lower Late-Life Body-Mass Index is Associated with Higher Cortical Amyloid Burden in Clinically Normal Elderly. J Alzheimers Dis 53:1097-105
Malishkevich, Anna; Marshall, Gad A; Schultz, Aaron P et al. (2016) Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers. J Alzheimers Dis 50:249-60
Hu, Chenhui; Sepulcre, Jorge; Johnson, Keith A et al. (2016) Matched signal detection on graphs: Theory and application to brain imaging data classification. Neuroimage 125:587-600
Maye, Jacqueline E; Betensky, Rebecca A; Gidicsin, Christopher M et al. (2016) Maternal dementia age at onset in relation to amyloid burden in non-demented elderly offspring. Neurobiol Aging 40:61-7
Hu, Chenhui; Cheng, Lin; Sepulcre, Jorge et al. (2015) A spectral graph regression model for learning brain connectivity of Alzheimer's disease. PLoS One 10:e0128136
Donovan, Nancy J; Hsu, David C; Dagley, Alexander S et al. (2015) Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults. J Alzheimers Dis 46:63-73
Gidicsin, Christopher M; Maye, Jacqueline E; Locascio, Joseph J et al. (2015) Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers. Neurology 85:48-55
Munro, Catherine E; Donovan, Nancy J; Guercio, Brendan J et al. (2015) Neuropsychiatric Symptoms and Functional Connectivity in Mild Cognitive Impairment. J Alzheimers Dis 46:727-35

Showing the most recent 10 out of 32 publications